Here's Why Illumina (ILMN) is a Strong Momentum Stock

Illumina (ILMN), a provider of genetic and genomic analysis solutions, is highlighted as a strong momentum stock, holding a Zacks #3 (Hold) rank but boasting an 'A' Momentum Style Score and a 'B' VGM Score. The company has seen its fiscal 2025 earnings consensus estimate increase by $0.17 to $4.42 per share, driven by seven upward analyst revisions in the last 60 days, alongside an average earnings surprise of +10.6%. This combination of strong momentum and positive earnings revisions suggests ILMN warrants consideration, particularly for momentum-focused investors.

Analysis

Illumina (ILMN) presents a compelling case for momentum-oriented analysis, underscored by its 'A' Momentum Style Score from Zacks. This is supported by a 1.8% share price increase over the last four weeks and, more significantly, by positive shifts in forward-looking earnings expectations. Specifically for fiscal 2025, seven analysts have revised their earnings estimates upward within the past 60 days, elevating the Zacks Consensus Estimate by $0.17 to $4.42 per share. This trend of positive revisions is complemented by the company's historical ability to outperform, evidenced by an average earnings surprise of +10.6%. However, these bullish momentum and earnings signals are tempered by the stock's neutral Zacks Rank of #3 (Hold), which, along with a 'B' VGM score, suggests that the stock may not be a top-tier candidate across all investment styles, such as value or growth, at this time.

Key Decisions for Investors

• Investors with a momentum-focused strategy should consider the positive signals from ILMN, specifically its 'A' grade for momentum and the recent upward trend in analyst earnings revisions.
• Monitor future analyst estimate revisions for fiscal 2025 closely, as the current positive momentum thesis is heavily dependent on the continuation of this upward trend.
• The neutral #3 (Hold) rating warrants a degree of caution, suggesting that while momentum is strong, other fundamental aspects may be less compelling, and a balanced position or further due diligence is prudent.